Literature DB >> 29330210

Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer.

Marwan G Fakih1.   

Abstract

Human epidermal growth factor 2 (HER2) amplification represents a distinct molecular subgroup of colorectal cancers that is associated with anti-epidermal growth factor receptor resistance and sensitivity to dual HER2 targeting. Although clinical trials have reported activity for trastuzumab/pertuzumab and trastuzumab/lapatinib combinations, there are no reports on lapatinib plus trastuzumab activity after resistance to trastuzumab plus pertuzumab. Presented are three cases of HER2 amplified colorectal cancer that developed acquired refractoriness to trastuzumab pertuzumab with subsequent clinical benefit to lapatinib plus trastuzumab, highlighting the potential for HER2 tyrosine kinase inhibition plus trastuzumab in overcoming trastuzumab/pertuzumab resistance. © AlphaMed Press 2018.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29330210      PMCID： PMC5896709          DOI： 10.1634/theoncologist.2017-0436

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  6 in total

1.  Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Authors:  Andrea Sartore-Bianchi; Livio Trusolino; Cosimo Martino; Katia Bencardino; Sara Lonardi; Francesca Bergamo; Vittorina Zagonel; Francesco Leone; Ilaria Depetris; Erika Martinelli; Teresa Troiani; Fortunato Ciardiello; Patrizia Racca; Andrea Bertotti; Giulia Siravegna; Valter Torri; Alessio Amatu; Silvia Ghezzi; Giovanna Marrapese; Laura Palmeri; Emanuele Valtorta; Andrea Cassingena; Calogero Lauricella; Angelo Vanzulli; Daniele Regge; Silvio Veronese; Paolo M Comoglio; Alberto Bardelli; Silvia Marsoni; Salvatore Siena
Journal:  Lancet Oncol       Date:  2016-04-20       Impact factor: 41.316

2.  Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.

Authors:  Simonetta M Leto; Francesco Sassi; Irene Catalano; Valter Torri; Giorgia Migliardi; Eugenia R Zanella; Mark Throsby; Andrea Bertotti; Livio Trusolino
Journal:  Clin Cancer Res       Date:  2015-08-21       Impact factor: 12.531

3.  Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

Authors:  Kimberly L Blackwell; Harold J Burstein; Anna Maria Storniolo; Hope S Rugo; George Sledge; Gursel Aktan; Catherine Ellis; Allison Florance; Svetislava Vukelja; Joachim Bischoff; José Baselga; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

4.  Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.

Authors:  André Robidoux; Gong Tang; Priya Rastogi; Charles E Geyer; Catherine A Azar; James N Atkins; Louis Fehrenbacher; Harry D Bear; Louis Baez-Diaz; Shakir Sarwar; Richard G Margolese; William B Farrar; Adam M Brufsky; Henry R Shibata; Hanna Bandos; Soonmyung Paik; Joseph P Costantino; Sandra M Swain; Eleftherios P Mamounas; Norman Wolmark
Journal:  Lancet Oncol       Date:  2013-10-04       Impact factor: 41.316

5.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Authors:  Andrea Bertotti; Giorgia Migliardi; Francesco Galimi; Francesco Sassi; Davide Torti; Claudio Isella; Davide Corà; Federica Di Nicolantonio; Michela Buscarino; Consalvo Petti; Dario Ribero; Nadia Russolillo; Andrea Muratore; Paolo Massucco; Alberto Pisacane; Luca Molinaro; Emanuele Valtorta; Andrea Sartore-Bianchi; Mauro Risio; Lorenzo Capussotti; Marcello Gambacorta; Salvatore Siena; Enzo Medico; Anna Sapino; Silvia Marsoni; Paolo M Comoglio; Alberto Bardelli; Livio Trusolino
Journal:  Cancer Discov       Date:  2011-09-02       Impact factor: 39.397

6.  HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.

Authors:  Susan D Richman; Katie Southward; Philip Chambers; Debra Cross; Jennifer Barrett; Gemma Hemmings; Morag Taylor; Henry Wood; Gordon Hutchins; Joseph M Foster; Assa Oumie; Karen G Spink; Sarah R Brown; Marc Jones; David Kerr; Kelly Handley; Richard Gray; Matthew Seymour; Philip Quirke
Journal:  J Pathol       Date:  2016-01-29       Impact factor: 7.996
  6 in total
  3 in total

Review 1.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

Review 2.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

3.  Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models.

Authors:  Jamunarani Veeraraghavan; Carolina Gutierrez; Vidyalakshmi Sethunath; Sepideh Mehravaran; Mario Giuliano; Martin J Shea; Tamika Mitchell; Tao Wang; Sarmistha Nanda; Resel Pereira; Robert Davis; Kristina Goutsouliak; Lanfang Qin; Carmine De Angelis; Irmina Diala; Alshad S Lalani; Chandandeep Nagi; Susan G Hilsenbeck; Mothaffar F Rimawi; C Kent Osborne; Rachel Schiff
Journal:  NPJ Breast Cancer       Date:  2021-05-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.